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Dioxin exposure has been associated with non-Hodgkin’s
lymphoma (NHL) in epidemiological investigations. The
NHL-related t(14;18) translocations can be detected at a
low copy number in lymphocytes from healthy subjects.
Exposure to NHL-associated carcinogens, such as dioxin or
pesticides, may cause expansion of t(14;18)-positive clones.
We investigated prevalence and frequency of circulating
t(14;18)-positive lymphocytes in 144 healthy subjects from
a population exposed to dioxin [plasma TCDD (2,3,7,8-
tetrachlorodibenzo-p-dioxin) range: <1.7–475.0 parts per
trillion (p.p.t.)] after the Seveso, Italy, accident of 1976.
t(14;18) translocations were measured in DNA from
peripheral blood lymphocytes by high-sensitivity real-
time quantitative polymerase chain reaction. We found
that the frequency, but not the prevalence, of t(14;18)
translocation-positive cells increased with increasing
plasma TCDD. Among t(14;18)-positive subjects (n ¼ 50;
34.7%), the mean number of t(14;18) translocations/106
lymphocytes was 4.2 [95% confidence interval (CI),
2.9–6.2] in subjects with plasma TCDD < 10.0 p.p.t., 8.1
(95% CI, 4.9–13.3) in subjects with plasma TCDD between
10.0 and 50.0 and 12.5 (95% CI, 7.4–21.1) in subjects with
plasma TCDD between 50.0 and 475.0 p.p.t. (P-trend ¼
0.003). As expected, t(14;18) frequency was associated
with cigarette smoking and was highest in subjects who
smoked for 16 years (mean ¼ 12.6; 95% CI, 7.4–21.3;
P ¼ 0.01). Higher t(14;18) prevalence was found among
individuals with fair hair color (P ¼ 0.01) and light eye
color (P¼ 0.04). No significant association between t(14;18)-
and age was found. Our results show that dioxin exposure
is associated with increased number of circulating t(14;18)
positive cells. Whether this change in t(14;18) frequency is
an indicator of elevated lymphoma risk remains speculat-
ive and needs further investigation for its potential impact
on public health.
Introduction
The incidence of non-Hodgkin’s lymphoma (NHL) has
increased over the past decades in Western countries (1).
More recently, this trend has leveled off in several countries,
possibly reflecting decreased exposures to organic pollutants
such as polychlorinated byphenyls (PCBs) or dioxins (2). The
etiology of the most common NHL types remains elusive.
Increased incidence of and mortality from NHL have been
reported in several investigations conducted on subjects
exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a
major environmental contaminant and known human carcino-
gen (3–8), thus suggesting a role for dioxin in NHL develop-
ment. TCDD is chemically related to other common
environmental contaminants that have been often associated
with increased risk of NHL, including pesticides (phenoxi-
acetic acid and chlorophenols), PCBs and other organohalogen
compounds.
More than 80–90% of follicular and 20% of diffuse large
lymphomas carry the t(14;18) translocation, the most frequent
chromosomal translocation in human lymphoid malignancies
(9). The t(14;18) translocation results from a reciprocal
translocation that juxtaposes the BCL-2 (B-Cell Leukemia/
Lymphoma 2) gene on chromosome 18q21 near the
immunoglobulin heavy chain (IgH) locus at chromosome
14q32 (10). In t(14;18), the anti-apoptotic BCL-2 gene
comes under the control of the IgH gene promoter, causing
overexpression of the BCL-2 protein (11). Analysis of the
junctional sequences has suggested that the translocation rep-
resents an early event in NHL development, occurring in pre-B
cells when attempting IgH rearrangement in the bone marrow
(12). In t(14;18) transgenic mice, the B-cell population has a
prolonged survival and polyclonal B-cell hyperplasia is uni-
formly observed, but only 5–15% of the animals develop
malignant lymphoma after a long latency (11).
In 30–80% of healthy individuals, highly-sensitive poly-
merase chain reaction (PCR) techniques have allowed for
the detection of a low number of t(14;18) copies in peripheral
blood lymphocytes and other normal lymphatic tissues
(12–14). High prevalence and frequency of t(14;18) translo-
cations in healthy subjects have been associated with individ-
ual characteristics, such as older age (15–17), hepatitis-C virus
(HCV) infection (18) and smoking (19,20). Also, an associa-
tion between t(14;18) translocation in B lymphocytes and
ultraviolet-B (UV-B) levels estimated from sunlight records
for the 3 weeks before blood sampling has been reported in a
study conducted on a limited number of healthy subjects (21),
while a later study by Roulland et al. (17) did not find any
variation in t(14;18) prevalence correlated with daily sunlight
Abbreviations: BCL-2, B-Cell leukemia/lymphoma 2; CI, confidence
interval; DL, detection limit; NHL, non-Hodgkin’s lymphoma; PCR,
polymerase chain reaction; RRT, relative retention time; TCDD, 2,3,7,8-
tetrachlorodibenzo-p-dioxin.
Carcinogenesis vol.27 no.10 pp.2001–2007, 2006
doi:10.1093/carcin/bgl011
Advance Access publication March 16, 2006
Published by Oxford University Press 2006 2001
data on a similar number of agriculture workers. Subjects’
pigmentation may have had a role in these associations.
The significance of the t(14;18) translocations found in healthy
subjects is unresolved. Progression toward the clinical disease
may occur by clonal expansion of existing t(14;18)-positive
cells, potentially promoted by intervening carcinogenic expo-
sures and associated with additional molecular and cytogenetic
events (22). The effect of a single chemical carcinogen spe-
cifically associated with NHL risk on circulating t(14;18)-
carrying cells has never been tested.
In 1976, an industrial accident contaminated a residential
area surrounding Seveso, Italy, with very high TCDD levels. In
multistage models for chemical carcinogenesis, TCDD acts
as a tumor promoter by reducing apoptosis (23) or increasing
growth rate and clonal expansion of initiated cells (24). TCDD
does not exhibit covalent binding to DNA, and tests for DNA
damage have been mostly negative (3). As in other dioxin-
exposed populations, NHL cases in excess of the expected
number were observed in Seveso among the exposed individu-
als (7,8). Many studies have advocated the role of epigenetic
alterations in cancer development (25). TCDD-mediated epi-
genetic disruptions may be the basis of TCDD–NHL associa-
tion. In particular, TCDD may have caused the expansion of
t(14;18)-positive clones in exposed subjects, leading to the
development of clinical NHL. To test this hypothesis, we
investigated whether body burdens of TCDD in healthy sub-
jects from the Seveso population influenced the prevalence and
frequency of circulating t(14;18)-positive cells. In addition, we
evaluated whether other selected subjects’ characteristics (age,
sex, pigmentation and smoking) and exposures may have con-




Subjects were selected from a population sample we described previously (26)
that included 211 healthy subjects representative of the Seveso area and 101
individuals who had developed well-documented chloracne, the typical skin
disorder consequent to intoxication from halogenated hydrocarbons, after the
accident. This population included exposed and unexposed subjects and had
dioxin levels that ranged from background levels to 475 parts per trillion
(p.p.t). (26) Subjects for the present study were selected from the original
study population so that two groups with high (>10 p.p.t.) or low (<10 p.p.t.)
current dioxin levels were formed. Seventy-two Caucasian subjects (52
females and 20 males) with current high-TCDD plasma levels (plasma
TCDD >10 p.p.t. lipid adjusted, equivalent to picograms/gram fat) and 72 sub-
jects (41 females, 31 males) with low plasma TCDD (<10 p.p.t.) were included
in the study. The cut-off of 10 p.p.t. is commonly considered to separate
background from elevated TCDD plasma levels (27–29). Except for chloracne,
the subjects did not have any history of major illnesses, including cancer, blood
disorders, allergies and chronic infectious diseases. The high- and low-TCDD
groups were frequency-matched by history of chloracne and cigarette smoking
status (never, former or current smoker) (Table I). However, average duration
of smoking in the low-TCDD group was 6.4 years longer than in the high-
TCDD group. As expected, a higher number of individuals in the high-TCDD
group were from the most contaminated zones (Zones A and B) of the Seveso
area. Subjects in the high-TCDD group had slightly older age, both at the
accident and at recruitment, than those in the low-TCDD group (Table I).
In the high-TCDD (>10 p.p.t.) group, current plasma TCDD concentrations
were between 10.5 and 475.0 p.p.t., with a geometric mean of 44.5 p.p.t. [95%
confidence interval (CI), 35.8–55.9). The low-TCDD (<10 p.p.t.) group
included (i) 23 subjects with detectable TCDD levels (plasma TCDD between
4.3 and 9.7 p.p.t.; geometric mean of 6.1 p.p.t.; 95% CI, 5.6–6.8); (ii) 49
subjects with plasma TCDD below the detection limit (DL) of the analytical
method, but with DL < 10 p.p.t. (DL range between 1.7 and 7.8 p.p.t.,
geometric mean of DL values ¼ 5.1; 95% CI, 4.5–5.8). The TCDD assay
has variable DL that depends, among other factors, on the amount of lipids that
can be extracted from the samples. The amount of lipids is related to the
amount of plasma available for the assay and on the blood lipid levels of
the individuals tested. In addition, the recovery of the analyte from the lipids
through the clean-up procedure can vary from sample to sample, affecting the
DL for that sample (30).
To assess dose–response trends, we used a three-category plasma TCDD
variable to test for the association between plasma TCDD and t(14;18) translo-
cation or frequency, by considering as reference the low-TCDD group and
dividing the high-TCDD group into two categories (plasma TCDD between
10.0 and 50.0 p.p.t., n ¼ 42; plasma TCDD between 50.0 and 475.0 p.p.t.,
n ¼ 30). Using the median value of 38.5 p.p.t. to divide the high-TCDD group
into two subgroups of 36 subjects each gave similar results. We chose the
50 p.p.t. cut-off value to include a larger range of dioxin levels in the second
category.
A questionnaire including data on demographics, lifestyle, foods consumed
at the time of the accident, residential history and occupations was adminis-
tered by trained interviewers, who also determined individual pigmentary
characteristics. We obtained written informed consent from all participants.
The local and U.S. National Cancer Institute’s Institutional Review Boards
reviewed and approved the study.
Real-time quantitative PCR
Whole blood was collected from donors into tubes treated with sodium heparin
and processed to obtain cryopreserved lymphocytes as described by Landi et al.
(31). DNA was extracted from lymphocytes, and real-time quantitative PCR
was carried out for the t(14;18)-MBR-translocation as described by Dolken
et al. (13) using the ABI PRISM 7700 Sequence Detection System (Applied
Biosystems, Darmstadt, Germany). 50-TGGTGGTTTGACCTTTAGAGA-30
(forward primer), 50-ACCTGAGGAGACGGTGAC-30 (reverse primer) and
50-CTCTGGGTGGGTCTGTGTTGAAACA-3’ (probe) were used for the
t(14;18)-MBR-PCR. The PCR mixture contained 400 nM of forward and
reverse primer, 200 nM probe, 4 mM MgCl2, 200 mM dATP, dCTP and
dGTP, 400 mM dUTP, 1.25 U AmpliTaq Gold, 0.5 U AmpErase UNG (uracil-
N-glycosylase) and 1· PCR buffer [50 mM KCl, 10 mM Tris-HCl (pH 8.3),
including 60 nM ROX in a total volume of 50 ml] and 0.6–1.0 mg DNA. All
reagents were obtained from Applied Biosystems. In addition to spectropho-
tometric measurements of DNA concentration, the number of cells tested in a
single PCR assay was determined by using the K-ras wild-type gene
as a reference gene. 50-CTTGTGGTAGTTGGAGCT-30 (forward primer),
50-ATCAAAGAATGGTCCTGC-30 (reverse primer) and 50-AAGAGTGCCT-
TGACGATACAGC-30 (probe) were used for K-ras real-time quantitative
PCR. Both probes were labeled with the reporter dye FAM
(6-carboxy-fluorescein) at the 50 end and the quencher dye TAMRA
(6-carboxy-tetramethylrhodamine) at the 30 end. After incubation at 50C
for 2 min to allow for UNG cleavage, AmpliTaq Gold was activated at
95C for 10 min. Each of the 50 PCR cycles consisted of 15 s at 95C and
1 min at 61C for combined annealing/extension. Standard curves were estab-
lished for quantification of t(14;18)-MBR-translocations and for K-ras wild-
type gene, as described previously (13). The standard procedure for every DNA
sample consisted of five replicates with 1 mg DNA for the detection of t(14;18)-
MBR-translocations and three replicates with 0.05 mg DNA for K-ras. For
samples with >5 mg DNA, the number of t(14;18) replicates was increased
so that the maximum DNA content per replicate remained 1 mg. Dilutions of
frozen aliquots of genomic DNA from the t(14;18)-MBR-positive cell line
Karpas 422 served as standards for both the t(14;18)-MBR and the K-ras
PCR. Each 96-well plate included two negative controls for each PCR
assay. The primer and MgCl2 concentration and the annealing temperature
of the real-time PCR assay used in this study were optimized so that reaction
conditions allowed only the amplification of specific translocation sequences.
In addition, the TaqMan real-time PCR system combines a set of primers with a
probe that hybridizes only and specifically to the target sequence.
Electrophoresis of PCR products
The amplification products of all t(14;18)-positive samples were analyzed by
agarose gel electrophoresis to identify samples with more than one t(14;18)-
positive clone. Sequencing analysis in an earlier study (13) confirmed that all
PCR products that were detected on the agarose gel were specific t(14;18)
translocation fragments.
Dioxin assay
TCDD was measured at the Centers for Disease Control and Prevention
(CDC), using a high-resolution gas chromatographic mass spectrometric anal-
ysis performed on human plasma. All dioxin measurements were performed in
the same testing facility by using the same assay, technology and standardized
procedures, as described previously (32). Criteria for a positive TCDD
determination were as follows: (i) signal/noise > 3/1 for both signals on
ions 320 and 322; (ii) signal/noise > 10/1 for both signals on ions 332 and
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334 from the internal standard; (iii) observed retention times within ±1 scan of
each other on ions 320 and 322 and the relative retention time (RRT) (to
[13C12]-2,3,7,8-TCDD) within 2 parts-per-thousand of the RRT of the ana-
lytical standard; (iv) ratios of the intensities of the ion 320–322 and 332–334
within the 95% CIs established for these ratios.
Statistical analysis
We defined t(14;18) prevalence as the proportion of individuals with a
t(14;18)-positive blood sample and t(14;18) frequency as the number of
t(14;18) copies per 106 lymphocytes. Univariate analysis was used to evaluate
the association of t(14;18) translocation with age, cigarette smoking and indi-
vidual pigmentary characteristics. We used the Fisher’s exact and the
Wilcoxon (Mann–Whitney) tests to assess differences in the t(14;18) preva-
lence and frequency, respectively. Because of its skewed distribution, the
number of t(14;18)-positive lymphocytes was expressed by using geometric
means and 95% CIs. Age and smoking have been previously associated with
both plasma TCDD levels (33,34) and t(14;18) translocations (15–17,19,20).
Thus, analyses based on variables correlated with dioxin exposure (i.e. plasma
TCDD, zone of residence or diagnosis of chloracne) were adjusted by age,
smoking status at recruitment (current smoker, ex-smoker or never smoker)
and duration of smoking. Because age at time of the Seveso accident has been
related with differential TCDD-elimination rates (26), and age at recruitment
was found to be associated with current TCDD plasma levels (34), we included
both age-variables in multivariate models. In multivariable analysis, we cal-
culated P-values and tests for trend for variations in t(14;18) prevalence by
means of unconditional logistic regression models. Adjusted geometric means
of t(14;18) frequency, 95% CIs and related P-values were computed by means
of linear multivariable regression models (procedure adjust in Stata 9.0) that
included the logarithm of the t(14;18) frequency as the dependent variable. We
performed all analyses using Stata 9.0 (Stata Corp., College Station, TX). All
reported P-values are two-sided.
Results
The t(14;18) translocation was found in peripheral blood
lymphocytes from 50 (34.7%) of the 144 subjects evaluated.
t(14;18) prevalence was not associated with age at the accident
(P ¼ 0.86), gender (P ¼ 0.14), cigarette smoking (P ¼ 0.23)
and duration of smoking (P ¼ 0.58) (Table II). Among
t(14;18)-positive subjects, the frequency of t(14;18) trans-
location did not show significant differences by age at the
accident (P ¼ 0.27) and gender (P ¼ 0.75). The mean number
of translocations/106 lymphocytes was 5.7 (95% CI, 3.8–8.5) in
never smokers, 6.2 (95% CI, 3.5–11.1) in ex-smokers and 9.2
(95% CI, 5.1–16.6) in current smokers (P-trend ¼ 0.12). Sub-
jects who reported a smoking duration of 16 years showed
higher mean t(14;18) frequency (12.6/106 lymphocytes;
95% CI, 7.4–21.3) than subjects who had smoked for no
more than 15 years (5.2/106 lymphocytes; 95% CI, 3.1–8.9)
(P¼ 0.01). No significant association with the average lifetime
number of cigarettes/day was seen (P ¼ 0.49) (Table II). Also,





% (Positive/total) Mean (95% CI)
Age at the accident
1–15 years 33.3 (24/72) 5.6 (3.7–8.2)
15–58 years 36.1 (26/72) 7.7 (5.3–11.3)
Gender
Male 43.1 (22/51) 6.4 (4.2–9.8)
Female 30.1 (28/93) 6.7 (4.6–9.7)
Cigarette smoking
Never 29.9 (23/77) 5.7 (3.8–8.5)
Ex-smoker 41.2 (14/34) 6.2 (3.5–11.1)
Current smoker 39.4 (13/33) 9.2 (5.1–16.6)
Cigarette number/day
1–10 40.5 (15/37) 6.9 (5.2–9.2)
11–40 40.0 (12/30) 8.5 (5.2–13.9)
Duration of smoking
1–15 years 40.0 (16/40) 5.2b (3.1–8.9)
16 or more years 40.7 (11/27) 12.6b (7.4–21.3)
aGeometric means and 95% CIs of the number of t(14;18)
translocations/106 lymphocytes among t(14;18)-positive subjects;.
bP ¼ 0.01, test for difference in mean t(14;18) frequency between
smoking duration categories.
Table I. Characteristics of the study subjects
Plasma TCDDa
Low (<10 p.p.t.) (n ¼ 72) High (>10 p.p.t.) (n ¼ 72) P-valueb
History of chloracnec
No, n (%) 46 (63.9) 45 (62.5)
Yes, n (%) 26 (36.1) 27 (37.5) 1.00
Cigarette smokingc
No, n (%) 38 (52.8) 39 (54.2)
Former, n (%) 18 (25.0) 16 (22.2)
Current, n (%) 16 (22.2) 17 (23.6) 0.95
Smoking duration (years), mean (SD) 20.4 (15.9) 14.0 (10.2) 0.17
Cigarette number/day, mean (SD) 12.3 (9.2) 10.6 (6.1) 0.74
Zone of residence at the time of the accidentd
A, n (%) 10 (13.9) 41 (56.9)
B, n (%) 7 (9.7) 27 (37.5)
R, n (%) 24 (33.3) 2 (2.8)
Reference, n (%) 31 (43.3) 2 (2.8) <0.001
Age at the accident,e mean (SD) 22.7 (18.1) 24.2 (17.9) 0.39
Age at recruitment,e mean (SD) 41.7 (17.0) 43.2 (17.2) 0.50
aTCDD plasma concentrations measured at the time of the study, in parts per trillion (p.p.t.), lipid-adjusted.
bTest for differences between low- and high-TCDD groups.
cSubjects with low- and high-TCDD levels were frequency-matched by history of chloracne and smoking status.
dDelimited after the accident based on TCDD soil concentrations with decreasing levels from Zones A–R, and non-detectable in the non-contaminated
Reference area.
eThe Seveso accident occurred on July 10, 1976. The study subjects were recruited 20 years later, from January 1993 through April 1998.
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no association was found with being a smoker at the time of the
accident and with the number of cigarettes smoked on the day
before the study (data not shown).
The prevalence of t(14;18) translocation did not differ by
plasma TCDD (Table III). The proportion of t(14;18)-positive
subjects was 34.7% both in the low- and the high-TCDD group
(P ¼ 0.69). When the high-TCDD group was divided into two
subgroups, the proportion of t(14;18)-positive subjects was
31.0% in the group with TCDD between 10.0 and 50.00
p.p.t. and 40.0% in the group with plasma TCDD between
50.0 and 475.0 p.p.t. (P-trend ¼ 0.47 across the three
plasma-TCDD categories). Nonetheless, among t(14;18)-positive
subjects, the translocation frequency was significantly higher
in subjects with elevated plasma TCDD levels (4.2 copies/106
lymphocytes, 95% CI, 2.9–6.2 in subjects with TCDD <
10.0 p.p.t.; and 9.9 copies/106 lymphocytes, 95% CI,
6.8–14.5 in subjects with TCDD between 10.0–475.0 p.p.t.;
P ¼ 0.006). When the subjects were categorized into three
plasma TCDD categories, by subdividing subjects with elevated
plasma TCDD into two groups, a trend in t(14;18) frequency
across TCDD categories was observed (Figure 1). The mean
number of translocations/106 lymphocytes was 4.2 (95% CI,
2.9–6.2) in subjects with plasma TCDD < 10.0 p.p.t., 8.1 (95%
CI, 4.9–13.3) in subjects with plasma TCDD between 10.0 and
50.0 and 12.5 p.p.t. (95% CI, 7.4–21.1) in subjects with plasma
TCDD levels between 50.0 and 475.0 p.p.t. (P-trend ¼ 0.003).
Consistently, the t(14;18) prevalence did not vary according
to the zone of residence at the time of the accident (P-trend ¼
0.89; and P ¼ 0.19 for Zone R versus Reference), but a
statistically significant trend was found when the translocation
frequency was evaluated (P-trend ¼ 0.04) (Table III). Past
history of chloracne was associated with neither t(14;18)
prevalence (P¼ 0.77) nor the frequency (P¼ 0.84) (Table III).
A higher proportion of subjects with detectable t(14;18)
translocations was found among individuals with medium/
light hair color (48.2%, 26 out of 54), relative to those with
dark hair color (23.4%, 18 out of 71; P ¼ 0.01). Similarly,
t(14;18) prevalence increased in subjects with lighter eye color
(24.6%, 14 out of 57 for dark; 39.3%, 22 out of 56 for medium;
and 45.2%, 14 out of 31 for light eye color; P-trend ¼ 0.03).
The t(14;18) prevalence was higher, though not significantly,
among individuals who reported that their skin usually burns
after 1 h of sun exposure (36.3%, 4 out of 21) than in those who
did not (19.0%, 41 out of 113) (P ¼ 0.14). The t(14;18) fre-
quency was not associated in t(14;18)-positive subjects with
hair color (P ¼ 0.76), eye color (P ¼ 0.77) or skin response
after 1 h in the sun (P ¼ 0.40). In addition, the t(14;18)
prevalence and frequency were not associated with presence
of freckles, freckling after sun exposure and history of sun-
burns (data not shown). The association between pigmentary
characteristics and t(14;18) did not change meaningfully after
the analyses were adjusted for plasma TCDD levels, age and
smoking status and duration.
Discussion
The finding that the t(14;18) translocation can be detected
in non-malignant circulating lymphocytes of healthy subjects
has fueled extensive debate on the role of the translocation in
NHL and, at large, on the biological steps underlying NHL
development. Although deregulated expression of the BCL-2
gene resulting from the t(14;18) translocation may represent
an early event in a pre-B stage cell contributing to cell
tumorigenicity, additional events, possibly involving expo-
sures to carcinogenic agents, are required for t(14;18)-positive
cells to develop a fully malignant phenotype (22).
In the present study conducted on subjects exposed to
TCDD after the Seveso accident, we found a significant
association between dioxin levels and the frequency of
t(14;18) translocation-positive cells. TCDD is a known cancer-
promoting agent and has been associated with increased NHL
risk in several epidemiology investigations (3–8). In our study
Table III. Prevalence and frequency of t(14;18) translocations by plasma




% (Positive/total) Mean (95% CI)
Plasma TCDD
<10 p.p.t. 34.7 (25/72) 4.2b (2.9–6.2)
10.0–475.0 p.p.t. 34.7 (25/72) 9.9b (6.8–14.5)
Zone of residence at the time of the accident
Reference 42.4 (14/33) 4.3c (2.3–8.0)
R 26.9 (7/26) 4.9c (2.2–10.7)
B 29.4 (10/34) 7.2c (3.8–13.6)
A 37.3 (19/51) 9.3c (5.8–14.8)
Chloracne after the accident
No 35.2 (32/91) 6.2 (3.7–10.6)
Yes 34.0 (18/53) 6.7 (4.7–9.6)
aGeometric means and 95% CIs of the number of t(14;18)
translocations/106 lymphocytes among t(14;18)-positive subjects,
adjusted for age, smoking status (never, ex or current smoker) and
smoking duration in multivariable analysis.
bP ¼ 0.006, test for difference in mean t(14;18) frequency between
plasma TCDD categories.
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Fig. 1. t(14;18) translocation frequency in t(14;18)-positive healthy
subjects (n ¼ 50) from the Seveso, Italy, population, by plasma TCDD
levels (P ¼ 0.003, test for trend across TCDD categories). t(14;18)
frequency is presented on a log-scale. Individual observations (dots), group
means (plus) and 95% CIs (dotted lines) are shown.
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we found that the frequency of t(14;18) translocations
increased in a dose-related manner with increasing levels of
plasma TCDD, indicating that TCDD exposure may have pro-
moted the expansion of existing t(14;18)-positive clones. The
lack of association with prevalence of t(14;18)-positive cells
may be related to the non-mutagenic properties of TCDD.
It has been suggested that t(14;18)-positive cells in healthy
individuals are under control of immunological mechanisms
(14,21). TCDD has been shown to affect both cell-mediated
and antibody immunity, and alterations of immune parameters
have been documented in the Seveso population (35). Modu-
lation of immune responses by TCDD may also have con-
tributed to the TCDD-associated changes in the number of
t(14;18)-bearing cells we observed in our study.
Because of the extremely long half-life of TCDD in humans
(7 years), TCDD plasma levels at the time of the study
reflected both past exposure levels and current body burden.
Thus, the increased number of t(14;18)-positive lymphocytes
in our study may have resulted from the effect of current
TCDD levels or long-lasting exposure to high body burdens
of TCDD.
In our study, the frequency of t(14;18)-positive lymphocytes
tended to be higher in smokers, particularly in those who had
longer smoking duration. In healthy subjects, smoking
has been previously correlated with higher frequency of
t(14;18)-positive cells in the blood (19) and increased propor-
tion of subjects with t(14;18)-positive bone-marrow samples
(20). t(14;18)-positive peripheral blood lymphocytes have
been found in eight out of eight subjects diagnosed with
persistent polyclonal B-cell lymphocytosis, a rare immunolo-
gical disorder observed mostly in women who are heavy smok-
ers (36). Whether this finding indicates increased risks of NHL
for smokers is uncertain.
We found a higher t(14;18) prevalence among individuals
with fair hair and eye color. Increased incidence of lymphomas
after UV-light exposure has been reported in mice (37,38), and
increased NHL risk has been associated with UV exposure in
some epidemiology investigations (39,40). However, recent
investigations have shown opposite results (41,42). One of
these studies (41) found reduced NHL risk in subjects with
history of high UV exposure, while light hair color was asso-
ciated with increased risk for follicular lymphoma. Unfortu-
nately, we do not have data on sun exposure in our study; thus,
we cannot verify the effect of sunlight exposure on translo-
cations in subjects with different pigmentation characteristics.
Our finding suggests that fair skin complexion may be
associated with early NHL-carcinogenesis events related to
t(14;18)-generation, and needs further investigation.
Although a slight increase by age was found, we could
not observe any significant association between age and
t(14;18)-positive lymphocytes. Some previous studies have
shown progressively higher prevalence of t(14;18) transloca-
tions in older healthy subjects (15–17), but several others did
not find any age-related change (20,43–45). Differences in
sample size, age range and populations investigated may
account for the conflicting results. In the Seveso population,
TCDD exposure and differential elimination by age of the
initial TCDD body burden may have reduced our capability
to detect age-related t(14;18) variations.
In the present study, we detected the t(14;18) translocation
in 34.7% of subjects. This proportion was similar to the
average estimate (36%) obtained by Schuler et al. (12) in
a meta-analysis of previous investigations that had evaluated
t(14;18) in peripheral blood cells from healthy individuals
either with no assessment of any specific exposure or in rela-
tion to radiation (46), domestic radon (47) or smoking (19). For
t(14;18) detection, the sensitivity and, consequently, the num-
ber of subjects testing positive for t(14;18) is related to the
amount of DNA used (12). In our study, we used an average
5 mg DNA and obtained a sensitivity of nearly 106 [i.e.
capability to detect one t(14;18) copy in 106 lymphocytes].
Using higher DNA amounts, Fuscoe et al. (44) obtained a
sensitivity for t(14;18) of 107 and detected the translocation
in peripheral blood mononuclear cells of 30 out of 34 (88%)
healthy subjects. On the basis of these data, it has been sug-
gested that every healthy individual might carry circulating
t(14;18)-positive cells that could be detected in peripheral
blood if the sensitivity is high enough or if enriched B-cell
fractions are used for DNA extraction (12). If this is the case,
the difference among individuals may be more related to the
frequency of positive cells than the simple detection of a
positive cell in the sample. Similarly, the known association
between age, HCV, smoking or UV-B light with prevalence of
translocations (15–21) might be the result of misclassification
of the translocations due to an assay with low sensitivity. The
finding that differences in the t(14;18) frequency, but not in the
t(14;18) prevalence, are associated with TCDD exposure may
indicate that TCDD operates at later stages of NHL develop-
ment by promoting proliferation or extending survival
in t(14;18)-positive clones that have already expanded to a
number of cells that exceeds the assay sensitivity threshold.
However, the significance of our findings with respect to indi-
vidual risk of NHL is uncertain. In our study, the frequency of
t(14;18)-positive cells remained within the range found in
healthy subjects by previous investigations (12,46), even in
the highest plasma TCDD level group. In addition, PCR-based
determination of t(14;18) frequency has been shown to be
highly reproducible when the initial number of t(14;18) copies
is 5, but greater between-replicate variations have been
observed at lower copy numbers (13). Thus, our results should
be used with caution, also considering that analyses were
based on a relatively small sample size.
In conclusion, TCDD exposure was related to increased
numbers of t(14;18)-positive circulating lymphocytes, but
not to the proportion of t(14;18)-positive subjects, in healthy
individuals from Seveso, Italy, suggesting that TCDD may
promote clonal expansion of non-malignant cells carrying
t(14;18). Other organohalogen compounds or pesticides
whose use has been associated with NHL risk might have
similar effects on lymphocytes. Whether this change in
t(14;18) frequency is an indicator of an elevated lymphoma
risk remains speculative, since prospective samples of dioxin-
exposed subjects who developed NHL are not available. How-
ever, this finding needs further investigation for its potential
impact on public health.
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